Regeneron Pharmaceuticals's latest marketcap:
As of 06/26/2025, Regeneron Pharmaceuticals's market capitalization has reached $55.05 B. According to our data, Regeneron Pharmaceuticals is the 392th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 55.05 B |
| Revenue (ttm) | 14.09 B |
| Net Income (ttm) | 4.5 B |
| Shares Out | 105.67 M |
| EPS (ttm) | 39.43 |
| Forward PE | 14.39 |
| Ex-Dividend Date | 05/20/2025 |
| Earnings Date | 07/31/2025 |
Regeneron Pharmaceuticals's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/26/2025 | $55.05 B | -27.97% | 392 |
| 12/31/2024 | $78.28 B | -18.19% | 223 |
| 12/29/2023 | $95.69 B | 21.78% | 153 |
| 12/30/2022 | $78.57 B | 15.69% | 170 |
| 12/31/2021 | $67.92 B | 31.74% | 259 |
| 12/31/2020 | $51.55 B | 25.04% | 300 |
| 12/31/2019 | $41.23 B | 1.98% | 328 |
| 12/31/2018 | $40.43 B | 0.08% | 265 |
| 12/29/2017 | $40.39 B | 4.33% | 304 |
| 12/30/2016 | $38.72 B | -31.47% | 247 |
Company Profile
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing innovative medicines for a wide range of diseases.
Key Products
- EYLEA Injection: Treats wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
- Dupixent Injection: Used for atopic dermatitis and asthma in adults and pediatric patients.
- Libtayo Injection: Targets metastatic or locally advanced cutaneous squamous cell carcinoma.
- Praluent Injection: For heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults.
- REGEN-COV: A treatment for COVID-19.
- Kevzara Solution: Addresses rheumatoid arthritis in adults.
- Inmazeb Injection: Treats infections caused by Zaire ebolavirus.
- ARCALYST Injection: For cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome.
- ZALTRAP Injection: Used intravenously for metastatic colorectal cancer.
- Evkeeza: A treatment for HoFH.
- Ordspono: For follicular lymphoma and diffuse large B-cell lymphoma.
- Veopoz: Targets CD55-deficient protein-losing enteropathy.
Research & Development
Regeneron is actively developing product candidates for eye diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain, and hematologic conditions.
Collaborations
- Partnered with Mammoth Biosciences, Inc. to research, develop, and commercialize in vivo CRISPR-based gene editing therapies.
- Collaborating with Sonoma Biotherapeutics, Inc. to discover and develop engineered regulatory T cell therapies.
Company Background
Founded in 1988, Regeneron is headquartered in Tarrytown, New York.
Frequently Asked Questions
-
What is Regeneron Pharmaceuticals's (REGN) current market cap?As of 06/26/2025, Regeneron Pharmaceuticals (including the parent company, if applicable) has an estimated market capitalization of $55.05 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Regeneron Pharmaceuticals (REGN) rank globally by market cap?Regeneron Pharmaceuticals global market capitalization ranking is approximately 392 as of 06/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.